Skip to main content
Erschienen in: Supportive Care in Cancer 11/2008

01.11.2008 | Short Communication

Osteonecrosis of the jaw (ONJ) in cancer patients treated with Bisphosphonates: how the knowledge of a phenomenon can change its evolution

verfasst von: Nicla La Verde, Claudia Bareggi, Marina Garassino, Karen Borgonovo, Paola Sburlati, Donata Pedretti, Celso Bianchi, Silvia Perrone, Dorian Mihali, Stefano Cobelli, Cristina Mantica, Aurora Rizzo, Gabriella Farina

Erschienen in: Supportive Care in Cancer | Ausgabe 11/2008

Einloggen, um Zugang zu erhalten

Abstract

Goals of the work

Osteonecrosis of the jaw (ONJ) is a severe complication of bisphosphonates treatment. Bisphosphonates reduce skeletal adverse events and give a clinical benefit to cancer patients. Therefore, it is necessary to identify appropriate procedures to reduce ONJ injures by using a successful monitoring program. In a retrospective study we analyzed the impact of a prevention program based on clinical oral cavity examination, dentists, and patients’ education. The aim of the study was to evaluate if this approach might improve ONJ outcome in patients receiving pamidronate or zoledronate.

Materials and methods

We analyzed retrospectively two different groups of patients treated at our Institution: patients treated from October 2003 to June 2005 (group A) and patients treated from June 2005 to April 2007 (group B). In June 2005 the prevention program started for all our patients.

Main results

One hundred and eighty-six cancer patients with bone involvement, treated with bisphosphonates, were considered. Sixteen of them developed ONJ: eight before and eight after June 2005. We observed a consistent difference in the evolution of the two groups. In the first group, four patients underwent a major surgery (one partial maxillectomy, complicated by septic shock and oronasal communication; two partial mandibulectomies; and one segmental mandibular resection), with an important impairment of their quality of life; while the eight new ONJ cases, diagnosed after June 2005, were successfully treated without aggressive dental interventions, and achieved a good control of symptoms.

Conclusions

Bisphosphonates-related ONJ is a frequent adverse event (8.6%). The monitoring program proved very efficient to improve the clinical outcome of ONJ, avoiding an aggressive treatment and using a conservative approach and medical therapy.
Literatur
2.
Zurück zum Zitat Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G et al (2005) Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23:8580–8587 doi:10.1200/JCO.2005.02.8670 PubMedCrossRef Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G et al (2005) Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23:8580–8587 doi:10.​1200/​JCO.​2005.​02.​8670 PubMedCrossRef
7.
Zurück zum Zitat Iguchi T, Miyakawa Y, Saito K, Nakabayashi C, Nakanishi M, Saya H et al (2007) Zoledronate-induced S phase arrest and apoptosis accompanied by DNA damage and activation of the ATM/Chk1/cdc25 pathway in human osteosarcoma cells. Int J Oncol 31(2):285–291PubMed Iguchi T, Miyakawa Y, Saito K, Nakabayashi C, Nakanishi M, Saya H et al (2007) Zoledronate-induced S phase arrest and apoptosis accompanied by DNA damage and activation of the ATM/Chk1/cdc25 pathway in human osteosarcoma cells. Int J Oncol 31(2):285–291PubMed
9.
Zurück zum Zitat Migliorati CA, Schubert MM, Peterson DE, Seneda LM (2005) Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 104(1):83–93 doi:10.1002/cncr.21130 PubMedCrossRef Migliorati CA, Schubert MM, Peterson DE, Seneda LM (2005) Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 104(1):83–93 doi:10.​1002/​cncr.​21130 PubMedCrossRef
13.
Zurück zum Zitat Takeyama S, Shinoda H (2003) Pharmacological actions and pharmacokinetics of bisphosphonates. Clin Calcium 13:115–121PubMed Takeyama S, Shinoda H (2003) Pharmacological actions and pharmacokinetics of bisphosphonates. Clin Calcium 13:115–121PubMed
14.
Zurück zum Zitat Weitzman R, Sauter N, Eriksen EF, Tarassoff PG, Lacerna LV, Dias R et al (2007) Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients-May 2006. Crit Rev Oncol Hematol 62(2):148–152 doi:10.1016/j.critrevonc.2006.12.005 PubMedCrossRef Weitzman R, Sauter N, Eriksen EF, Tarassoff PG, Lacerna LV, Dias R et al (2007) Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients-May 2006. Crit Rev Oncol Hematol 62(2):148–152 doi:10.​1016/​j.​critrevonc.​2006.​12.​005 PubMedCrossRef
15.
Zurück zum Zitat Woo SK, Hellstein JW, Kalmar JR (2006) Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144:753–761PubMed Woo SK, Hellstein JW, Kalmar JR (2006) Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144:753–761PubMed
Metadaten
Titel
Osteonecrosis of the jaw (ONJ) in cancer patients treated with Bisphosphonates: how the knowledge of a phenomenon can change its evolution
verfasst von
Nicla La Verde
Claudia Bareggi
Marina Garassino
Karen Borgonovo
Paola Sburlati
Donata Pedretti
Celso Bianchi
Silvia Perrone
Dorian Mihali
Stefano Cobelli
Cristina Mantica
Aurora Rizzo
Gabriella Farina
Publikationsdatum
01.11.2008
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 11/2008
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-008-0484-3

Weitere Artikel der Ausgabe 11/2008

Supportive Care in Cancer 11/2008 Zur Ausgabe

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Klinik aktuell Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.